Trial Profile
Sunitinib Treatment Of Renal Adjuvant Cancer (s-TRAC): A Randomized Double-Blind Phase 3 Study Of Adjuvant Sunitinib Vs. Placebo In Subjects At High Risk Of Recurrent RCC
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Jun 2022
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms S-TRAC; S-TRAC
- Sponsors Pfizer
- 16 May 2022 Systemic and meta-analysis from six trials (KEYNOTE-564, S-TRAC, ASSURE, PROTECT, ATLAS, and SORCE) presented at the 117th Annual Meeting of the American Urological Association
- 16 Jun 2020 Results assessing retrospective, post-hoc exploratory analysis investigated the neutrophil-to-lymphocyte ratio 52 (NLR) for predictive and prognostic significance in the RCC adjuvant settingpublished in the Clinical Cancer Research
- 06 Nov 2018 Results published in the Clinical Cancer Research